Tisento Therapeutics has dosed the first subject in its Phase IIb PRIZM study, examining the effects of the oral investigational therapy, zagociguat, on mitochondrial encephalomyopathy, lactic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback